Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

α-Synuclein stimulation of monoamine oxidase-B and legumain protease mediates the pathology of Parkinson's disease.

Kang SS, Ahn EH, Zhang Z, Liu X, Manfredsson FP, Sandoval IM, Dhakal S, Iuvone PM, Cao X, Ye K.

EMBO J. 2018 May 16. pii: e201798878. doi: 10.15252/embj.201798878. [Epub ahead of print]

PMID:
29769405
2.

C/EBPβ regulates delta-secretase expression and mediates pathogenesis in mouse models of Alzheimer's disease.

Wang ZH, Gong K, Liu X, Zhang Z, Sun X, Wei ZZ, Yu SP, Manfredsson FP, Sandoval IM, Johnson PF, Jia J, Wang JZ, Ye K.

Nat Commun. 2018 May 3;9(1):1784. doi: 10.1038/s41467-018-04120-z.

3.

Silencing Alpha Synuclein in Mature Nigral Neurons Results in Rapid Neuroinflammation and Subsequent Toxicity.

Benskey MJ, Sellnow RC, Sandoval IM, Sortwell CE, Lipton JW, Manfredsson FP.

Front Mol Neurosci. 2018 Feb 13;11:36. doi: 10.3389/fnmol.2018.00036. eCollection 2018.

4.

Induction of alpha-synuclein pathology in the enteric nervous system of the rat and non-human primate results in gastrointestinal dysmotility and transient CNS pathology.

Manfredsson FP, Luk KC, Benskey MJ, Gezer A, Garcia J, Kuhn NC, Sandoval IM, Patterson JR, O'Mara A, Yonkers R, Kordower JH.

Neurobiol Dis. 2018 Apr;112:106-118. doi: 10.1016/j.nbd.2018.01.008. Epub 2018 Jan 16.

PMID:
29341898
5.

Subthalamic Nucleus Deep Brain Stimulation Does Not Modify the Functional Deficits or Axonopathy Induced by Nigrostriatal α-Synuclein Overexpression.

Fischer DL, Manfredsson FP, Kemp CJ, Cole-Strauss A, Lipton JW, Duffy MF, Polinski NK, Steece-Collier K, Collier TJ, Gombash SE, Buhlinger DJ, Sortwell CE.

Sci Rep. 2017 Nov 27;7(1):16356. doi: 10.1038/s41598-017-16690-x.

6.

Can STN DBS protect both nigral somata and innervation of the striatum?

Fischer DL, Manfredsson FP, Sortwell CE.

Ann Neurol. 2017 Nov;82(5):855. doi: 10.1002/ana.25064. Epub 2017 Oct 26. No abstract available.

PMID:
28985650
7.

TrkB neurotrophic activities are blocked by α-synuclein, triggering dopaminergic cell death in Parkinson's disease.

Kang SS, Zhang Z, Liu X, Manfredsson FP, Benskey MJ, Cao X, Xu J, Sun YE, Ye K.

Proc Natl Acad Sci U S A. 2017 Oct 3;114(40):10773-10778. doi: 10.1073/pnas.1713969114. Epub 2017 Sep 18.

8.

Rationally Engineered AAV Capsids Improve Transduction and Volumetric Spread in the CNS.

Kanaan NM, Sellnow RC, Boye SL, Coberly B, Bennett A, Agbandje-McKenna M, Sortwell CE, Hauswirth WW, Boye SE, Manfredsson FP.

Mol Ther Nucleic Acids. 2017 Sep 15;8:184-197. doi: 10.1016/j.omtn.2017.06.011. Epub 2017 Jun 21.

9.

Delta-Secretase Phosphorylation by SRPK2 Enhances Its Enzymatic Activity, Provoking Pathogenesis in Alzheimer's Disease.

Wang ZH, Liu P, Liu X, Manfredsson FP, Sandoval IM, Yu SP, Wang JZ, Ye K.

Mol Cell. 2017 Sep 7;67(5):812-825.e5. doi: 10.1016/j.molcel.2017.07.018. Epub 2017 Aug 17.

PMID:
28826672
10.

Asparagine endopeptidase cleaves α-synuclein and mediates pathologic activities in Parkinson's disease.

Zhang Z, Kang SS, Liu X, Ahn EH, Zhang Z, He L, Iuvone PM, Duong DM, Seyfried NT, Benskey MJ, Manfredsson FP, Jin L, Sun YE, Wang JZ, Ye K.

Nat Struct Mol Biol. 2017 Aug;24(8):632-642. doi: 10.1038/nsmb.3433. Epub 2017 Jul 3.

11.

Loss of α-Synuclein Does Not Affect Mitochondrial Bioenergetics in Rodent Neurons.

Pathak D, Berthet A, Bendor JT, Yu K, Sellnow RC, Orr AL, Nguyen MK, Edwards RH, Manfredsson FP, Nakamura K.

eNeuro. 2017 Apr 28;4(2). pii: ENEURO.0216-16.2017. doi: 10.1523/ENEURO.0216-16.2017. eCollection 2017 Mar-Apr.

12.

α-Synuclein binds and sequesters PIKE-L into Lewy bodies, triggering dopaminergic cell death via AMPK hyperactivation.

Kang SS, Zhang Z, Liu X, Manfredsson FP, He L, Iuvone PM, Cao X, Sun YE, Jin L, Ye K.

Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):1183-1188. doi: 10.1073/pnas.1618627114. Epub 2017 Jan 17.

13.

Impact of age and vector construct on striatal and nigral transgene expression.

Polinski NK, Manfredsson FP, Benskey MJ, Fischer DL, Kemp CJ, Steece-Collier K, Sandoval IM, Paumier KL, Sortwell CE.

Mol Ther Methods Clin Dev. 2016 Dec 7;3:16082. eCollection 2016.

14.

Quantitative and semi-quantitative measurements of axonal degeneration in tissue and primary neuron cultures.

Kneynsberg A, Collier TJ, Manfredsson FP, Kanaan NM.

J Neurosci Methods. 2016 Jun 15;266:32-41. doi: 10.1016/j.jneumeth.2016.03.004. Epub 2016 Mar 28.

15.

Continuous Collection of Adeno-Associated Virus from Producer Cell Medium Significantly Increases Total Viral Yield.

Benskey MJ, Sandoval IM, Manfredsson FP.

Hum Gene Ther Methods. 2016 Feb;27(1):32-45. doi: 10.1089/hgtb.2015.117.

PMID:
26863210
16.

Is Alpha-Synuclein Loss-of-Function a Contributor to Parkinsonian Pathology? Evidence from Non-human Primates.

Collier TJ, Redmond DE Jr, Steece-Collier K, Lipton JW, Manfredsson FP.

Front Neurosci. 2016 Jan 29;10:12. doi: 10.3389/fnins.2016.00012. eCollection 2016.

17.

The contribution of alpha synuclein to neuronal survival and function - Implications for Parkinson's disease.

Benskey MJ, Perez RG, Manfredsson FP.

J Neurochem. 2016 May;137(3):331-59. doi: 10.1111/jnc.13570. Epub 2016 Mar 23. Review.

18.

Viral Vector-Based Modeling of Neurodegenerative Disorders: Parkinson's Disease.

Fischer DL, Gombash SE, Kemp CJ, Manfredsson FP, Polinski NK, Duffy MF, Sortwell CE.

Methods Mol Biol. 2016;1382:367-82. doi: 10.1007/978-1-4939-3271-9_26.

PMID:
26611600
19.

Gene Therapy of the Peripheral Nervous System: The Enteric Nervous System.

Benskey MJ, Manfredsson FP.

Methods Mol Biol. 2016;1382:263-74. doi: 10.1007/978-1-4939-3271-9_19.

PMID:
26611593
20.

Intraparenchymal Stereotaxic Delivery of rAAV and Special Considerations in Vector Handling.

Benskey MJ, Manfredsson FP.

Methods Mol Biol. 2016;1382:199-215. doi: 10.1007/978-1-4939-3271-9_14.

PMID:
26611588
21.

Lentivirus Production and Purification.

Benskey MJ, Manfredsson FP.

Methods Mol Biol. 2016;1382:107-14. doi: 10.1007/978-1-4939-3271-9_8.

PMID:
26611582
22.

Introduction to Viral Vectors and Other Delivery Methods for Gene Therapy of the Nervous System.

Manfredsson FP.

Methods Mol Biol. 2016;1382:3-18. doi: 10.1007/978-1-4939-3271-9_1.

PMID:
26611575
23.

High-Frequency Stimulation of the Rat Entopeduncular Nucleus Does Not Provide Functional or Morphological Neuroprotection from 6-Hydroxydopamine.

Fischer DL, Collier TJ, Cole-Strauss A, Wohlgenant SL, Lipton JW, Steece-Collier K, Manfredsson FP, Kemp CJ, Sortwell CE.

PLoS One. 2015 Jul 29;10(7):e0133957. doi: 10.1371/journal.pone.0133957. eCollection 2015.

24.

Intrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration.

Paumier KL, Luk KC, Manfredsson FP, Kanaan NM, Lipton JW, Collier TJ, Steece-Collier K, Kemp CJ, Celano S, Schulz E, Sandoval IM, Fleming S, Dirr E, Polinski NK, Trojanowski JQ, Lee VM, Sortwell CE.

Neurobiol Dis. 2015 Oct;82:185-199. doi: 10.1016/j.nbd.2015.06.003. Epub 2015 Jun 17.

25.

The longitudinal transcriptomic response of the substantia nigra to intrastriatal 6-hydroxydopamine reveals significant upregulation of regeneration-associated genes.

Kanaan NM, Collier TJ, Cole-Strauss A, Grabinski T, Mattingly ZR, Winn ME, Steece-Collier K, Sortwell CE, Manfredsson FP, Lipton JW.

PLoS One. 2015 May 20;10(5):e0127768. doi: 10.1371/journal.pone.0127768. eCollection 2015.

26.

A method for combining RNAscope in situ hybridization with immunohistochemistry in thick free-floating brain sections and primary neuronal cultures.

Grabinski TM, Kneynsberg A, Manfredsson FP, Kanaan NM.

PLoS One. 2015 Mar 20;10(3):e0120120. doi: 10.1371/journal.pone.0120120. eCollection 2015.

27.

Targeted gene delivery to the enteric nervous system using AAV: a comparison across serotypes and capsid mutants.

Benskey MJ, Kuhn NC, Galligan JJ, Garcia J, Boye SE, Hauswirth WW, Mueller C, Boye SL, Manfredsson FP.

Mol Ther. 2015 Mar;23(3):488-500. doi: 10.1038/mt.2015.7. Epub 2015 Jan 16.

28.

Recombinant adenoassociated virus 2/5-mediated gene transfer is reduced in the aged rat midbrain.

Polinski NK, Gombash SE, Manfredsson FP, Lipton JW, Kemp CJ, Cole-Strauss A, Kanaan NM, Steece-Collier K, Kuhn NC, Wohlgenant SL, Sortwell CE.

Neurobiol Aging. 2015 Feb;36(2):1110-20. doi: 10.1016/j.neurobiolaging.2014.07.047. Epub 2014 Oct 13.

29.

The role of parkin in the differential susceptibility of tuberoinfundibular and nigrostriatal dopamine neurons to acute toxicant exposure.

Benskey MJ, Manfredsson FP, Lookingland KJ, Goudreau JL.

Neurotoxicology. 2015 Jan;46:1-11. doi: 10.1016/j.neuro.2014.11.004. Epub 2014 Nov 20.

30.

Neuroprotective potential of pleiotrophin overexpression in the striatonigral pathway compared with overexpression in both the striatonigral and nigrostriatal pathways.

Gombash SE, Manfredsson FP, Mandel RJ, Collier TJ, Fischer DL, Kemp CJ, Kuhn NM, Wohlgenant SL, Fleming SM, Sortwell CE.

Gene Ther. 2014 Jul;21(7):682-93. doi: 10.1038/gt.2014.42. Epub 2014 May 8.

31.

Morphological and behavioral impact of AAV2/5-mediated overexpression of human wildtype alpha-synuclein in the rat nigrostriatal system.

Gombash SE, Manfredsson FP, Kemp CJ, Kuhn NC, Fleming SM, Egan AE, Grant LM, Ciucci MR, MacKeigan JP, Sortwell CE.

PLoS One. 2013 Nov 27;8(11):e81426. doi: 10.1371/journal.pone.0081426. eCollection 2013.

32.

Differential sensitivity of cranial and limb motor function to nigrostriatal dopamine depletion.

Plowman EK, Maling N, Rivera BJ, Larson K, Thomas NJ, Fowler SC, Manfredsson FP, Shrivastav R, Kleim JA.

Behav Brain Res. 2013 Jan 15;237:157-63. doi: 10.1016/j.bbr.2012.09.031. Epub 2012 Sep 24.

33.

Regulated protein expression for in vivo gene therapy for neurological disorders: progress, strategies, and issues.

Manfredsson FP, Bloom DC, Mandel RJ.

Neurobiol Dis. 2012 Nov;48(2):212-21. doi: 10.1016/j.nbd.2012.03.001. Epub 2012 Mar 9. Review.

PMID:
22426391
34.

Loss of functional alpha-synuclein: a toxic event in Parkinson's disease?

Kanaan NM, Manfredsson FP.

J Parkinsons Dis. 2012;2(4):249-67. doi: 10.3233/JPD-012138. Review.

35.

Striatal pleiotrophin overexpression provides functional and morphological neuroprotection in the 6-hydroxydopamine model.

Gombash SE, Lipton JW, Collier TJ, Madhavan L, Steece-Collier K, Cole-Strauss A, Terpstra BT, Spieles-Engemann AL, Daley BF, Wohlgenant SL, Thompson VB, Manfredsson FP, Mandel RJ, Sortwell CE.

Mol Ther. 2012 Mar;20(3):544-54. doi: 10.1038/mt.2011.216. Epub 2011 Oct 18.

36.

The development of flexible lentiviral vectors for gene transfer in the CNS.

Manfredsson FP, Mandel RJ.

Exp Neurol. 2011 Jun;229(2):201-6. doi: 10.1016/j.expneurol.2011.03.013. Epub 2011 Apr 1.

PMID:
21459087
37.

α-Synuclein expression in rat substantia nigra suppresses phospholipase D2 toxicity and nigral neurodegeneration.

Gorbatyuk OS, Li S, Nguyen FN, Manfredsson FP, Kondrikova G, Sullivan LF, Meyers C, Chen W, Mandel RJ, Muzyczka N.

Mol Ther. 2010 Oct;18(10):1758-68. doi: 10.1038/mt.2010.137. Epub 2010 Jul 27.

38.

In vivo RNAi-mediated alpha-synuclein silencing induces nigrostriatal degeneration.

Gorbatyuk OS, Li S, Nash K, Gorbatyuk M, Lewin AS, Sullivan LF, Mandel RJ, Chen W, Meyers C, Manfredsson FP, Muzyczka N.

Mol Ther. 2010 Aug;18(8):1450-7. doi: 10.1038/mt.2010.115. Epub 2010 Jun 15.

39.

Development of gene therapy for neurological disorders.

Manfredsson FP, Mandel RJ.

Discov Med. 2010 Mar;9(46):204-11. Review.

40.
41.

Tight Long-term dynamic doxycycline responsive nigrostriatal GDNF using a single rAAV vector.

Manfredsson FP, Burger C, Rising AC, Zuobi-Hasona K, Sullivan LF, Lewin AS, Huang J, Piercefield E, Muzyczka N, Mandel RJ.

Mol Ther. 2009 Nov;17(11):1857-67. doi: 10.1038/mt.2009.196. Epub 2009 Aug 25.

42.

Nigrostriatal rAAV-mediated GDNF overexpression induces robust weight loss in a rat model of age-related obesity.

Manfredsson FP, Tumer N, Erdos B, Landa T, Broxson CS, Sullivan LF, Rising AC, Foust KD, Zhang Y, Muzyczka N, Gorbatyuk OS, Scarpace PJ, Mandel RJ.

Mol Ther. 2009 Jun;17(6):980-91. doi: 10.1038/mt.2009.45. Epub 2009 Mar 10.

43.

AAV9: a potential blood-brain barrier buster.

Manfredsson FP, Rising AC, Mandel RJ.

Mol Ther. 2009 Mar;17(3):403-5. doi: 10.1038/mt.2009.15. No abstract available.

44.

Striatal readministration of rAAV vectors reveals an immune response against AAV2 capsids that can be circumvented.

Peden CS, Manfredsson FP, Reimsnider SK, Poirier AE, Burger C, Muzyczka N, Mandel RJ.

Mol Ther. 2009 Mar;17(3):524-37. doi: 10.1038/mt.2008.284. Epub 2009 Jan 13.

45.

The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease.

Gorbatyuk OS, Li S, Sullivan LF, Chen W, Kondrikova G, Manfredsson FP, Mandel RJ, Muzyczka N.

Proc Natl Acad Sci U S A. 2008 Jan 15;105(2):763-8. doi: 10.1073/pnas.0711053105. Epub 2008 Jan 4.

46.

rAAV-mediated nigral human parkin over-expression partially ameliorates motor deficits via enhanced dopamine neurotransmission in a rat model of Parkinson's disease.

Manfredsson FP, Burger C, Sullivan LF, Muzyczka N, Lewin AS, Mandel RJ.

Exp Neurol. 2007 Oct;207(2):289-301. Epub 2007 Jul 10.

PMID:
17678648
47.

Time course of transgene expression after intrastriatal pseudotyped rAAV2/1, rAAV2/2, rAAV2/5, and rAAV2/8 transduction in the rat.

Reimsnider S, Manfredsson FP, Muzyczka N, Mandel RJ.

Mol Ther. 2007 Aug;15(8):1504-11. Epub 2007 Jun 12.

48.

Recombinant adeno-associated viral vectors as therapeutic agents to treat neurological disorders.

Mandel RJ, Manfredsson FP, Foust KD, Rising A, Reimsnider S, Nash K, Burger C.

Mol Ther. 2006 Mar;13(3):463-83. Epub 2006 Jan 18. Review.

49.

RNA knockdown as a potential therapeutic strategy in Parkinson's disease.

Manfredsson FP, Lewin AS, Mandel RJ.

Gene Ther. 2006 Mar;13(6):517-24. Review.

PMID:
16267570

Supplemental Content

Loading ...
Support Center